Introduction & Cassava Sciences

This blog was setup to promote small cap bios in the Alzheimers and CNS spaces. Many small biotechs are forced to battle misinformation from social media scientists, wall street short sellers and pump & dump traders. This leads to attacks on the credibility of founders and scientists and causes extreme volatility in share prices.

In such scenarios, some small retail investors who have done their due diligence and who may have critical information to share, often struggle to disseminate information that counters the narrative. For instance these investors may tweet at a widely followed account of a social media scientist or write a comment on the authors blog and receive no responses. Sometimes the errors propagated may be so egregious and even acknowledged by the social media figure but then no follow up actions or corrections are made.

What this blog will specifically do for investors?

• Provide a platform for vetted retail investors to publish scientific views that counter the prevailing social media sentiment on small cap bios
• Research the science and provide general insights/opinions including critque of the critics
• Provide a Q&A with experts in the field

What this blog will not do?

• Be a platform for unscientific views or promote any sort of hate or misogyny
• Receive any sort of in kind donation from investors or companies and people associated

The author(s) on this blog may hold short/long positions on the stocks.

The first company we will be covering is Cassava Sciences (Ticker: SAVA), a small cap bio, with its lead drug candidate Simufilam and plasma biomarker candidate SavaDx. A recent FDA petition filed by law firm Labaton Sucharow called into question the science behind the company and asked to halt its phase 3 trials. We will be examining the truth to the allegations using crowdsourced knowledge and responses from Cassava sciences (here and more recently here).

We hope you are open to our views!